CYT006-AngQb
Also known as: AngQb, Anti-angiotensin II vaccine, CYT006, CYT006‑AngQb
Source CYT006-AngQb at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
CYT006‑AngQb is an investigational vaccine that couples angiotensin II to virus‑like particles. It is designed to stimulate the immune system to produce antibodies that neutralise circulating angiotensin II, thereby lowering blood pressure in people with hypertension.
Mechanism of Action
The conjugate presents angiotensin II epitopes on a virus‑like particle scaffold, prompting B‑cell activation and the generation of anti‑angiotensin II antibodies. These antibodies bind endogenous angiotensin II, preventing its interaction with AT1 receptors on vascular smooth muscle and adrenal tissue, which reduces vasoconstriction, aldosterone secretion and overall blood‑pressure elevation.
What the Research Shows
Early‑phase clinical work (Phase I/II) has shown that three subcutaneous doses of 300 µg CYT006‑AngQb are safe and can lower ambulatory blood pressure compared with placebo, with early‑morning systolic reductions of about ‑25 mm Hg and diastolic reductions of ‑13 mm Hg. Smaller trials reported modest average drops of ‑9/‑4 mm Hg. The vaccine’s effect is less pronounced than that of standard RAS‑blocking drugs, and larger Phase II studies are ongoing to confirm efficacy and durability. Reproducibility with more frequent dosing has been problematic, and further optimisation of immunogen and adjuvant is considered necessary.
Reported Benefits
If effective, the vaccine could provide long‑lasting blood‑pressure control with dosing intervals of months, improving adherence for patients who struggle with daily pills. Early data suggest it can achieve clinically meaningful reductions, especially in the early‑morning period when cardiovascular events peak, and it may be useful for pre‑hypertensive individuals or in settings where drug supply is limited.
Limitations of the Evidence
Evidence is limited to small early‑phase trials; the magnitude of blood‑pressure reduction is modest and not consistently reproducible with different dosing schedules. The vaccine has not matched the potency of approved ACE inhibitors or ARBs, and long‑term safety, durability of antibody response, and optimal formulation remain unresolved.
Safety Considerations
Phase I/II studies reported CYT006‑AngQb to be safe and well tolerated, with no serious adverse events noted. Nonetheless, animal data from other RAAS vaccines have raised concerns about autoimmune reactions, and the long‑term safety profile in humans has not yet been established, warranting further monitoring in larger trials.
How It Is Administered
CYT006‑AngQb is administered subcutaneously, typically as three 300 µg injections given a few weeks apart. The intended regimen aims for booster doses every four to six months, using a virus‑like particle formulation to present the angiotensin II antigen.
Routes of Administration
Goals & Uses
- Hypertension controlCardiovascularModerate
- Morning blood pressure surge attenuationCardiovascularModerate
- Long-term antihypertensive control with infrequent dosingCardiovascular / AdherenceLow
- Blood pressure reduction in arterial hypertensionCardiovascularModerate
Contraindications
- Immunocompromised stateImmuneModerate
- Autoimmune diseaseImmuneModerateMay worsen or interact with immune-mediated disease
- Severe renal artery stenosisRenal/VascularHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Known hypersensitivity to vaccine components or bacteriophage proteinsImmunologicalHigh
- Severe hypotensionCardiovascularHigh
Adverse Effects
- Flu-like symptomsSystemic/ImmunologicalCommon
- Mild hypotensionSystemicUncommon
- Flu‑like symptomsSystemicUncommon
- Injection site reactionsLocalCommon
- Injection‑site painLocalCommon
- HypotensionCardiovascularUncommonLow blood pressure
- Renal function impairmentRenalRare
Drug Interactions
- Angiotensin‑II receptor blockers (ARBs)Moderate
- Angiotensin Receptor Blockers (ARBs)Moderate
- ACE inhibitorsModerate
- DiureticsLowMay worsen dehydration or electrolyte imbalance
- ImmunosuppressantsModeratePotential interaction with immune pathways or infection risk
- Potassium-sparing diureticsModerate
Population Constraints
- Pediatric patientsAgeAbsolute
- Children (<18 y)AgeAbsolute
- Pregnant or lactating womenReproductiveAbsolute
- Immunocompromised patientsImmunologicRelative
- Pregnant womenReproductiveAbsolute
- Patients with severely compromised renal functionRenalRelative
Regulatory Status
- European UnionInvestigationalUnder clinical evaluation; not authorized by EMA.
- United StatesInvestigationalInvestigational New Drug (IND) status; no FDA approval.
- United KingdomInvestigationalClinical trial material; no MHRA marketing authorization.
Completed Phase II trials in several countries; not approved by FDA, EMA or MHRA.
Evidence & Sources
- Journal ArticleModerateBrown MJ2009-01-01T00:00:00.000000Z
- Journal ArticleModerateBairwa M, et al.2014-01-01T00:00:00.000000Z
- Journal ArticleModeratePandey R, et al.2009-01-01T00:00:00.000000Z
- Journal ArticleModerateMaurer P, Bachmann MF2010-01-01T00:00:00.000000Z
- Journal ArticleModerateBrown MJ2008-01-01T00:00:00.000000Z
- Journal ArticleModerateDo TH, et al.2010-01-01T00:00:00.000000Z
Frequently Asked Questions
How does CYT006‑AngQb differ from conventional antihypertensive drugs?
Conventional drugs block the renin‑angiotensin system pharmacologically, requiring daily dosing. CYT006‑AngQb seeks to induce an immune response that continuously neutralises angiotensin II, allowing dosing only a few times per year.
What blood‑pressure reductions have been observed in human studies?
Early trials reported average reductions of about ‑9 mm Hg systolic and ‑4 mm Hg diastolic, with a more pronounced early‑morning drop of roughly ‑25 mm Hg systolic and ‑13 mm Hg diastolic after three doses.
Is the vaccine approved for clinical use?
No. CYT006‑AngQb remains investigational and is currently being evaluated in Phase II clinical trials; it has not received regulatory approval for any indication.
Are there any known safety concerns?
Phase I/II data indicate the vaccine is well tolerated with no serious adverse events, but long‑term safety and the risk of autoimmune reactions have not been fully established.
Who might benefit most from this approach?
Patients who have difficulty adhering to daily antihypertensive medication, or those in low‑resource settings where long‑acting, infrequently administered therapy could improve hypertension control.
What is CYT006-AngQb?
CYT006‑AngQb is an investigational vaccine that couples angiotensin II to virus‑like particles. It is designed to stimulate the immune system to produce antibodies that neutralise circulating angiotensin II, thereby lowering blood pressure in people with hypertension.
What is CYT006-AngQb used for?
CYT006-AngQb is educationally associated with: Hypertension control, Morning blood pressure surge attenuation, Long-term antihypertensive control with infrequent dosing, Blood pressure reduction in arterial hypertension. Educational only — not medical advice.
How is CYT006-AngQb administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of CYT006-AngQb?
Reported adverse effects include: Flu-like symptoms, Mild hypotension, Flu‑like symptoms, Injection site reactions, Injection‑site pain, Hypotension, Renal function impairment. This list is not exhaustive — consult a qualified clinician.
Who should avoid CYT006-AngQb?
Recorded contraindications: Immunocompromised state, Autoimmune disease, Severe renal artery stenosis, Pregnancy, Known hypersensitivity to vaccine components or bacteriophage proteins, Severe hypotension. Consult a qualified clinician before use.